enalapril / Generic mfg. - LARVOL DELTA

Cycloastragenol Attenuates Angiotensin II-Induced Cardiac Remodeling in Association with Enhanced EGFR Lysosomal Turnover and Changes in MAPK Signaling and Autophagy. (PubMed, Pharmaceuticals (Basel)) - "Male C57BL/6 mice subjected to continuous Ang II infusion at 500 ng/kg/min for 28 days were used to establish the in vivo cardiac remodeling model and evaluate the effects of CAG on cardiac function, myocardial injury, fibrosis, inflammation, oxidative stress, apoptosis, and autophagy-related changes, with enalapril used as a positive control...The K716R mutation attenuated CAG-associated changes in EGFR turnover, MAPK phosphorylation, and autophagic flux. These findings suggest that CAG attenuates Ang II-induced cardiac remodeling and is associated with enhanced EGFR lysosomal turnover, accompanied by changes in MAPK signaling and autophagy-related processes."

Journal • Cardiovascular • Congestive Heart Failure • Fibrosis • Heart Failure • Immunology • Inflammation • Targeted Protein Degradation • EGFR

Comparison of oral enalapril-hydrochlorothiazide and oral nifedipine in treating postpartum hypertension: An open label randomised controlled trial. (PubMed, Am J Obstet Gynecol MFM) - "Enalapril-hydrochlorothiazide provided greater blood pressure reduction and reduced the need for additional antihypertensive therapy compared with nifedipine in the management of postpartum hypertension."

Journal • Cardiovascular • Hypertension

Overcoming formulation challenges of a moisture-sensitive API using Tricalcium citrate TB and anhydrous Trimagnesium citrate in direct compression. (PubMed, Eur J Pharm Sci) - "Enalapril maleate (EM) was chosen as a model drug, as it degrades rapidly when mixed with moisture-containing excipients, disintegrants or water...Further, we confirmed the scalability of the most promising direct tableting formulations to a rotary press. Our research demonstrated that using TCC TB in combination with TMC yields outstanding results regarding powder flowability, tablet tensile strength while also maintaining a rapid disintegration and ensuring superior formulation stability."

Journal

Elevated Prorenin Induces Podocyte Injury and Glomerular Fibrosis in cyp1a1-Prorenin Transgenic Rats. (PubMed, Int J Mol Sci) - "Treatment with either amlodipine or enalapril for 6 weeks prevented the development of hypertension and partially attenuated podocyte injury, albuminuria, and renal fibrosis, without fully reversing these changes. These protective effects were associated with suppression of NF-κB- and Nox2-mediated inflammatory and oxidative stress pathways. Collectively, these findings demonstrate that prorenin promotes podocyte injury and glomerular fibrosis through mechanisms that are partially dependent on hypertension and angiotensin II but also involve angiotensin II-independent pathways."

Journal • Preclinical • Cardiovascular • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Fibrosis • Glomerulonephritis • Hypertension • Immunology • Metabolic Disorders • Nephrology • Renal Disease • CYP1A1

Recurrent Episodes of New-Onset Supraventricular Tachycardia in Severe Early-Onset Pre-eclampsia and Fetal Growth Restriction: A Report of a Complex Cardio-Obstetric Case. (PubMed, Cureus) - "She was subsequently stabilised on bisoprolol and enalapril, with no further documented SVT episodes before discharge. Furthermore, it demonstrates that delivery is not always the definitive solution to complex obstetric pathology, as significant maternal cardiovascular morbidity may persist beyond the immediate postpartum period. Finally, the case emphasises the importance of listening to maternal concerns regarding fetal well-being, even when initial assessments are reassuring, and recognising the need for ongoing psychological support and counselling following traumatic pregnancy complications."

Journal • Anesthesia • Cardiovascular • Critical care • Gynecology • Hypertension • Obstetrics • Ventricular Tachycardia

A Randomized Trial of Sacubitril/Valsartan versus Enalapril in Chronic Chagas Cardiomyopathy with Reduced Ejection Fraction: Results of the ANSWER-HF Biomarker Subanalysis (AHA 2026) - "Abstract is embargoed at this time."

Biomarker • Clinical • Cardiomyopathy • Cardiovascular

A Cohort Study on Incidence and Factors Associated With Adverse Drug Reactions of Enalapril in Lusaka, Zambia. (PubMed, Pharmacol Res Perspect) - "These findings have clinical relevance for prescribing and monitoring ACEIs in sub-Saharan African populations. Further studies are needed to confirm this signal and explore underlying mechanisms."

Adverse drug reaction • Journal • Cardiovascular • Cough • Respiratory Diseases

Effects of sacubitril/valsartan versus enalapril on NT-proBNP and hs-troponin T in patients with heart failure due to Chagas disease: insights from the PARACHUTE-HF trial (ESC 2026) - "CONCLUSION In patients with HFrEF due to Chagas disease, sacubitril/valsartan led to a greater and sustained reduction in NT-proBNP compared with enalapril. A decrease in NT-proBNP likely reflects reduced cardiac filling pressures and myocardial wall stress, consistent with favorable hemodynamic effects of sacubitril/valsartan."

Clinical • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypertension

Low-Normal Hemoglobin Concentrations and Clinical Outcomes in Heart Failure. (PubMed, J Am Coll Cardiol) - P3 | "In patients with HF, hemoglobin concentrations associated with the lowest risk of death and HF hospitalization were approximately 14 g/dL in women and 15 g/dL in men. Hemoglobin concentrations above WHO anemia thresholds may still carry prognostic information and, in conjunction with other clinical findings, may prompt consideration of potentially reversible contributors such as iron deficiency. (Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity [CHARM-Added], NCT00634309; Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity [CHARM-Alternative], NCT00634400; Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity [CHARM-Preserved], NCT00634712; A Comparison Of Outcomes In Patients In New York Heart Association [NYHA] Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines [EMPHASIS-HF], NCT00232180; Irbesartan in..."

Clinical data • Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • Hematological Disorders

PARADIGM-HF eligibility in historical German HFrEF populations: clinical characteristics and 1-year outcomes. (PubMed, Int J Cardiol) - "In these historical German HFrEF datasets, full PARADIGM-HF eligibility including NP criteria was confirmed in 41.2% of patients with completely assessable eligibility information, indicating that PARADIGM-HF included a high rate of patients seen in routine care. PARADIGM-like compared to non-PARADIGM-like patients exhibited a more advanced clinical profile."

Journal • Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Heart Failure

The Study on Effects of Sacubitril-Valsartan on Left Ventricular Ejection Fraction, Myocardial Biomarker, and Myocardial Remodeling in Patients with Heart Failure with Reduced Ejection Fraction. (PubMed, J Cardiovasc Echogr) - "Sacubitril/Valsartan therapy improves LVEF and LV structural dynamics in HFrEF patients, supporting its role as a superior alternative to enalapril. These findings align with evidence of approximately 20% relative risk reduction in sudden cardiac death and heart failure-related mortality among patients with an ejection fraction <40% and elevated natriuretic peptides."

Biomarker • Journal • Cardiovascular • Congestive Heart Failure • Diabetes • Heart Failure • Metabolic Disorders

Sacubitril/Valsartan versus enalapril in heart failure due to chagas cardiomyopathy: a systematic review of randomized controlled trials (ESC 2026) - "In patients with HFrEF due to Chagas cardiomyopathy, sacubitril/valsartan improves biomarkers but does not reduce cardiovascular death or heart failure hospitalization compared with enalapril. These findings contrast with non-Chagas HFrEF and underscore the distinct inflammatory and fibrotic pathophysiology of Chagas cardiomyopathy. Disease-specific therapeutic strategies targeting immune and parasitic mechanisms are needed."

Clinical • Review • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure

Renin-Angiotensin System Inhibitor Use and Mortality in Older Hypertensive Patients With and Without Dementia: A Nationwide Registry-Based Cohort Study. (PubMed, J Clin Hypertens (Greenwich)) - "Cox regressions compared mortality risk among RASI users versus non-users, ACEI users versus ARB users, and users of enalapril, ramipril, losartan, and candesartan versus other RASI users. RASI use was associated with lower all-cause mortality among older hypertensive patients, including those with dementia. These observational findings support continued attention to evidence-based hypertension treatment in patients with dementia."

Journal • Alzheimer's Disease • Cardiovascular • CNS Disorders • Dementia • Hypertension

Perioperative Management of Urgent Colectomy in a Patient With Recent Myocardial Infarction, Stroke, and Reduced Ejection Fraction (ASA 2026) - "The patient was receiving aspirin, clopidogrel, metoprolol, and enalapril. Intraoperative management required transfusion of two units of packed red blood cells. The patient was admitted to the ICU postoperatively and had a favorable clinical outcome without cardiovascular complications."

Clinical • Cardiovascular • Colon Adenocarcinoma • Colon Cancer • Colorectal Adenocarcinoma • Colorectal Cancer • Ischemic stroke • Myocardial Infarction

Sunshine Biopharma Inc…announced on Wednesday that it has secured regulatory approval to introduce its generic Enalapril tablets across the Canadian market, signaling a significant strategic step into first-line antihypertensive treatments. (Yahoo Finance)

Canada approval • Hypertension

Relapse of Steroid-Dependent Nephrotic Syndrome Despite Long-Term Ciclosporin Therapy in an 11-Year-Old Child: A Case Report and Review on the Management of Nephrotic Syndrome in Children. (PubMed, Case Rep Nephrol) - "He had experienced 11 previous relapses and was receiving ciclosporin 50 mg twice daily and enalapril 5 mg once daily with good adherence...Penicillin V was initiated for spontaneous bacterial peritonitis prophylaxis...This case highlights several important therapeutic considerations in relapsing childhood nephrotic syndrome: recognition of SDNS as a subgroup of SSNS, accurate prednisolone dosing during relapse, careful assessment of edema and intravascular volume status before diuretic therapy, and individualized use of steroid-sparing agents and antimicrobial prophylaxis. In children receiving prolonged ciclosporin therapy, treatment should be regularly reviewed with blood pressure, renal function, and therapeutic drug monitoring in view of potential calcineurin inhibitor toxicity, and alternative steroid-sparing options such as levamisole may be considered where clinically appropriate."

Journal • Cough • Glomerulonephritis • Hematological Disorders • Infectious Disease • Nephrology • Renal Disease • Respiratory Diseases • Thrombocytosis

Enalapril, Atenolol, Alendronate and DRESS Syndrome - A Case Report. (PubMed, Acta Derm Venereol) - No abstract available

Journal

Sacubitril/Valsartan versus Enalapril or Losartan at Maximum Doses in Heart Failure with Reduced Ejection Fraction: Real-World Data. (PubMed, Arq Bras Cardiol) - "This real-world study did not demonstrate significant reductions in hospitalization or mortality for sacubitril/valsartan compared with enalapril or losartan at guideline-recommended maximum dosages; however, sacubitril/valsartan was associated with improved functional status."

Clinical • Journal • Observational data • Real-world evidence • Cardiovascular • Congestive Heart Failure • Heart Failure

Digital pharmacoepidemiology of angiotensin-converting enzyme inhibitors in Russia. (PubMed, Front Pharmacol) - "Search queries were analyzed for six major ACE inhibitors (captopril, enalapril, lisinopril, perindopril, ramipril, fosinopril), as well as for their brand names (21 drugs in total). The identified digital patterns may indirectly reflect medication-related information needs and potential gaps in the population's health literacy. The infodemiological approach represents a promising tool for monitoring patients' information needs and optimizing clinical communication and preventive programs."

Journal • Cardiovascular • Hypertension

CAPP-E: Cardiovascular Protection After Preeclampsia With Enalapril (clinicaltrials.gov) - P3 | N=60 | Recruiting | Sponsor: Women and Infants Hospital of Rhode Island | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Gynecology • Hypertension

Scleroderma Renal Crisis and Posterior Reversible Encephalopathy Syndrome Triggered by Non-steroidal Anti-inflammatory Drugs. (PubMed, Intern Med) - "Treatment included enalapril, hemodialysis, and plasma exchange. This case highlights the potential role of NSAIDs in the development of SRC, and emphasizes the importance of considering NSAIDs as a significant risk factor for SRC in patients with SSc."

Journal • CNS Disorders • Hematological Disorders • Immunology • Nephrology • Renal Disease • Scleroderma • Systemic Sclerosis • Thrombocytopenia

Multimodal Raman and Fluorescence Lifetime Imaging: A New Analytical Approach for Resolving Timing-Dependent Metabolic Recovery in Endothelial Dysfunction. (PubMed, Anal Chem) - "Chemometric analysis utilizing principal component analysis, partial least-squares regression, and semiquantitative lipid profiling revealed a pronounced timing-dependent response to enalaprilat...These findings demonstrate that early intervention leads to analytically distinguishable molecular states, underscoring the relevance of temporal profiling in endothelial diagnostics. By establishing a multimodal spectroscopic and chemometric framework, this work highlights the analytical power of integrative imaging for resolving subtle metabolic phenotypes and refining strategies for the objective evaluation of therapeutic efficacy."

Journal • Metabolic Disorders

Case Report: The effect of early initiation of eteplirsen treatment on the cardiac and motor disease course in an individual with Duchenne muscular dystrophy. (PubMed, Front Pediatr) - "At 24 months of age, weekly intravenous eteplirsen therapy was initiated, along with enalapril to manage cardiac symptoms. Despite persistent hyperlordosis and waddling gait, his 6-minute walk test remained stable. To our knowledge, this is the first documented case of DMD reporting cardiac outcomes after eteplirsen treatment in a patient as young as 24 months of age."

Journal • Cardiomyopathy • Cardiovascular • Duchenne Muscular Dystrophy • Genetic Disorders • Muscular Dystrophy

Size-dependent interfacial retention of vaterite particles under tear flow: Linking hydrodynamic detachment to ocular pharmacodynamics. (PubMed, Colloids Surf B Biointerfaces) - "Two structurally equivalent particle fractions were engineered: micron-sized (3.8 ± 0.5 µm) and submicron (0.65 ± 0.15 µm) particles with preserved vaterite phase stability in simulated tear fluid, porous architecture, comparable surface physicochemical properties, matched enalaprilat loading (∼5 wt%), and diffusion-controlled release kinetics...Overall, this work identifies particle size as a key parameter of interfacial retention under flow and suggests that reducing hydrodynamic detachment at mucosal interfaces can enhance ocular pharmacodynamic performance without increasing the administered drug dose. The presented framework provides a basis for rational design of interface-controlled drug delivery systems beyond empirical formulation approaches."

Journal • PK/PD data

Treatment Outcome and Associated Factors among Chronic Kidney Disease Patients at Zewditu Memorial Hospital and Tikur Anbessa Specialized Hospital: A Retrospective Cross-Sectional Study. (PubMed, Biomed Hub) - "Enalapril and amlodipine were prescribed for 39.0% and 37.3% of patients, respectively, and polypharmacy was observed in 53.3% of patients with stage five CKD. A substantial proportion of patients  with CKD had complications, including hospitalization and ESRD. Polypharmacy was prevalent among patients with advanced CKD, underscoring the need for comprehensive management and close monitoring to improve treatment outcomes."

Journal • Observational data • Retrospective data • Chronic Kidney Disease • Nephrology • Renal Disease